Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
GL
Monte Rosa Therapeutics, Inc. Common Stock
GLUE
Mkt Cap
$831.0M
Volume
662.89K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
GL
GLUE
GL
Monte Rosa Therapeutics, Inc. Common Stock
GLUE
News
·
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight
Mkt Cap
$863.4M
Volume
662.89K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight
The molecular glues market is experiencing significant growth with over 80 active players developing 90+ pipeline candidates. Key companies including Revolution Medicines, Gluetacs Therapeutics, Captor Therapeutics, and others are advancing promising molecular glue degraders across oncology, immunology, and neurodegenerative diseases. Recent developments include FDA Breakthrough Therapy Designation for Daraxonrasib and multiple clinical trial initiations, positioning molecular glues as a promising therapeutic strategy for previously undruggable proteins.
GlobeNewswire Inc. · Jul 23, 2026
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company developing molecular glue degrader medicines, announced it will participate in two investor conferences in May and June 2026, including fireside chats at the TD Cowen Oncology Innovation Summit and Jefferies Global Healthcare Conference. The company is advancing its pipeline of first-in-class MGD therapies with three programs currently in clinical development.
GlobeNewswire Inc. · May 20, 2026
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher
Despite a growing sentiment favoring industrial and dividend stocks in 2026, three high-risk stocks that surged over 100% in 2025 continue to show upside potential. FTAI Aviation benefits from GE Aerospace and Palantir partnerships, Kratos Defense gains from defense sector positioning, and Monte Rosa Therapeutics shows promise from positive clinical trial data. All three trade near or below analyst price targets with further upside expected.
Investing.com · Feb 6, 2026
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company developing molecular glue degrader medicines, announced pricing of an underwritten public offering of 11.125 million shares at $24.00 per share and 1.375 million pre-funded warrants, expected to raise approximately $300 million gross proceeds. The offering is expected to close on January 12, 2026.
GlobeNewswire Inc. · Jan 9, 2026
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
Monte Rosa Therapeutics presented preclinical data on MRT-8102, a molecular glue degrader targeting NEK7, which shows potential in treating cardiovascular and cardiometabolic diseases by modulating the NLRP3 inflammasome pathway.
GlobeNewswire Inc. · Nov 8, 2025
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics announced CEO Markus Warmuth will participate in multiple healthcare investor conferences in November and December 2025, presenting the company's molecular glue degrader (MGD) research and developments.
GlobeNewswire Inc. · Nov 3, 2025
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
Monte Rosa Therapeutics presented preclinical data on MRT-6160, a molecular glue degrader targeting VAV1, showing potential to treat multiple autoimmune and inflammatory diseases like systemic lupus erythematosus and rheumatoid arthritis in mouse models.
GlobeNewswire Inc. · Oct 24, 2025
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Monte Rosa Therapeutics announced a collaboration with Novartis to develop novel AI-powered degraders for immune-mediated diseases, receiving $120 million upfront and potential milestone payments up to $5.7 billion.
Benzinga · Sep 15, 2025
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
Monte Rosa Therapeutics signed a collaboration agreement with Novartis to develop novel molecular glue degraders for immune-mediated diseases, receiving a $120 million upfront payment and potential milestone payments up to $5.7 billion.
GlobeNewswire Inc. · Sep 15, 2025
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
Monte Rosa Therapeutics initiated a Phase 1 clinical study for MRT-8102, a molecular glue degrader targeting NEK7 for treating inflammatory diseases. The study includes single and multiple ascending dose cohorts in healthy volunteers, with initial results expected in H1 2026.
GlobeNewswire Inc. · Jul 21, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
GL
GLUE
Monte Rosa Therapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
GLUE
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any GLUE yet.
Related Tickers
Earnings